WallStSmart

AMN Healthcare Services Inc (AMN)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1668% more annual revenue ($60.44B vs $3.42B). AZN leads profitability with a 17.2% profit margin vs -0.9%. AZN appears more attractively valued with a PEG of 1.33. AZN earns a higher WallStSmart Score of 64/100 (C+).

AMN

Buy

62

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 6.3Quality: 5.5
Piotroski: 4/9Altman Z: 2.27

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AMNUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$48.75

Current Price

$34.70

$14.05 discount

UndervaluedFair: $48.75Overvalued
AZNUndervalued (+10.7%)

Margin of Safety

+10.7%

Fair Value

$193.96

Current Price

$173.30

$20.66 discount

UndervaluedFair: $193.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMN3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
99.9%10/10

Revenue surging 99.9% year-over-year

EPS GrowthGrowth
321.3%10/10

Earnings expanding 321.3% YoY

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$261.94B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.7%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

AMN4 concerns · Avg: 3.0/10
PEG RatioValuation
1.714/10

Expensive relative to growth rate

Market CapQuality
$1.33B3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.093/10

Elevated debt levels

Return on EquityProfitability
-4.5%2/10

ROE of -4.5% — below average capital efficiency

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
25.4x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMN

The strongest argument for AMN centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 99.9% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : AMN

The primary concerns for AMN are PEG Ratio, Market Cap, Debt/Equity.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AMN profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.

AMN carries more volatility with a beta of 0.41 — expect wider price swings.

AMN is growing revenue faster at 99.9% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 62/100), backed by strong 17.2% margins and 12.5% revenue growth. AMN offers better value entry with a 59.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AMN Healthcare Services Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

AMN Healthcare Services, Inc. provides healthcare personnel solutions and staffing services to hospitals and healthcare facilities in the United States. The company is headquartered in Dallas, Taxas.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?